Takeda Pharmaceutical Co ADR (TAK)

Takeda Pharmaceutical Co ADR Borsa (TAK) Ultime notizie

Takeda and AC Immune ink $2.1 billion Alzheimer's therapy deal - Investing.com India

Investing.com India

Takeda stock down 1% as operating profit declines - Investing.com India

Investing.com India

Proton Pump Inhibitors Market In-depth Analysis, Rising Business Opportunities And Estimated Forecast Till 2031 ... - openPR

openPR

Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround

Zacks Investment Research

Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround

Zacks Investment Research

All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy

Zacks Investment Research

TAK or CTLT: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Zacks Investment Research

Best Value Stocks to Buy for April 25th

Zacks Investment Research

Best Income Stocks to Buy for April 25th

Zacks Investment Research

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

Zacks Investment Research

Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

TAK or STVN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Zacks Investment Research

Weekly Upgrades and Downgrades - InvestorPlace

InvestorPlace

Weekly Upgrades and Downgrades - InvestorPlace

InvestorPlace

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

Zacks Investment Research

One Ultra-Cheap High-Yield Dividend Stock to Buy

The Motley Fool

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach

Benzinga

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Zacks Investment Research

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Zacks Investment Research

MORF Stock Collapses 55% Over Two Days As Takeda Rivalry Slams Ulcerative Colitis Drug - Investor's Business Daily

Investor's Business Daily

CDSCO raises alert on fake Adcetris injection manufactured by Takeda Pharma - Medical Dialogues

Medical Dialogues

CDSCO raises alert on fake Lymphoma drug Adcetris Injection manufactured by Takeda Pharma - Medical Dialogues

Medical Dialogues

Big Pharma keeps on coming to Boston: 'That's where the action is' - Boston Business Journal - The Business Journals

The Business Journals

CDMO: Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole! - StockNews.com

StockNews.com

IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space ... - GlobeNewswire

GlobeNewswire

6 Undervalued Stocks With Low Beta - Morningstar

Morningstar

Takeda Stock: Undervalued And Potential Upside (NYSE:TAK) - Seeking Alpha

Seeking Alpha

Nichi-Iko Pharma seeks debt restructuring aided by white knight - Nikkei Asia

Nikkei Asia

Revealed: the pharma companies best equipped with AI - Clinical Trials Arena

Clinical Trials Arena

Top 20 Pharmaceutical Companies by Revenue 2021 - FiercePharma

FiercePharma

Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U

New Trader U

The top 15 pharma companies by 2026 sales - FiercePharma

FiercePharma

Here are the drugs the FDA says are OK to take in place of recalled Zantac - Fox Business

Fox Business

How Takeda CEO Sells Japan's Biggest Deal to Doubters - Bloomberg

Bloomberg

Nektar Therapeutics Stock Is Risky But Offers Big Reward - InvestorPlace

InvestorPlace